Redhill Biopharma Shares Up 26% After Co. Announces Positive Top-Line Results From Phase III Study Of RHB-104 For Crohn's Disease, Meeting Primary And Key Secondary Endpoints And Demonstrating Statistically Significant Benefit Over Placebo
Benzinga Newsdesk